Hematologic Toxicity Is Rare in Relapsed Patients Treated With Belinostat: A Systematic Review of Belinostat Toxicity and Safety in Peripheral T-Cell Lymphomas

Cancer Management and Research - New Zealand
doi 10.2147/cmar.s149241
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Informa UK Limited

Related search

MDS as a Cause for Prolonged Hematologic Toxicity After Treatment With Cd19 Targeted Car-T Cell Therapy in Patients With Relapsed Refractory Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Preclinical Efficacy of Belinostat in Combination With Zidovudine in Adult T-Cell Leukemia-Lymphoma

Retrovirology
VirologyInfectious Diseases
2015English

Tanslocations Involving Cd28 Are Rare in Peripheral T-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Single Center Phase II Study of Ixazomib in Patients With Relapsed or Refractory Cutaneous or Peripheral T-Cell Lymphomas

American Journal of Hematology
Hematology
2017English

Survival Benefit With Novel Agents in Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas (Ptcl): The Columbia University Experience

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

High-Dose Therapy With Autologous Stem Cell Transplantation in Patients With Peripheral T Cell Lymphomas

Bone Marrow Transplantation
TransplantationHematology
2001English

Kir3dl2 Is Expressed in Peripheral T-Cell Lymphomas and May Be a Therapeutic Target

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Pralatrexate in Patients With Recurrent or Refractory Peripheral T-Cell Lymphomas: A Multicenter Retrospective Analysis

Scientific Reports
Multidisciplinary
2019English

Guest Editorial: Peripheral T-Cell Lymphomas: Progress Is Not “Peripheral”, but “Central”

International Journal of Hematology
Hematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy